Valuation: Center Laboratories, Inc.

Market Cap 27.77B 871M 764M 704M 659M 1.24B 82.19B 1.26B 8.46B 3.27B 40.62B 3.27B 3.2B 141B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 31.81B 998M 875M 807M 755M 1.42B 94.15B 1.45B 9.69B 3.75B 46.53B 3.75B 3.67B 161B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
73.35%
Yield 2024
1.71%
Yield 2025 4.21%
1 day-1.72%
Current month-2.75%
1 month-1.33%
3 months-10.14%
6 months+0.27%
Current year-10.58%
1 week 36.8
Extreme 36.8
38.75
1 month 36.8
Extreme 36.8
39.4
Current year 36.8
Extreme 36.8
51.4
1 year 33.1
Extreme 33.1
51.4
3 years 29.12
Extreme 29.1236
58.79
5 years 29.12
Extreme 29.1236
58.79
10 years 20.99
Extreme 20.9884
64.21
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Chief Tech/Sci/R&D Officer - 01/07/1983
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%0.00%+2.45%-19.09% 871M
+7.13%+9.97%+51.94%+166.83% 1,077B
+3.99%+11.50%+67.53%+55.63% 613B
+4.20%+17.03%+35.63%+87.74% 448B
+0.99%+4.85%+27.93%+22.82% 332B
+1.82%+8.19%+41.15%+26.80% 293B
+0.22%+6.75%+31.51%+42.02% 286B
+0.73%+8.53%-26.22%-40.85% 215B
+1.56%+6.14%+28.38%+59.45% 193B
+3.26%+3.33%+18.83%+67.03% 159B
Average +1.69%+7.27%+27.91%+46.84% 361.69B
Weighted average by Cap. +2.26%+8.93%+40.50%+81.26%

Financials

2024 2025
Net sales 1.62B 50.76M 44.5M 41.02M 38.41M 72.02M 4.79B 73.51M 493M 191M 2.37B 191M 186M 8.21B 1.52B 47.57M 41.71M 38.44M 35.99M 67.49M 4.49B 68.89M 462M 179M 2.22B 179M 175M 7.69B
Net income -1.1B -34.63M -30.36M -27.98M -26.2M -49.13M -3.27B -50.15M -336M -130M -1.61B -130M -127M -5.6B 9.32B 292M 256M 236M 221M 415M 27.59B 424M 2.84B 1.1B 13.64B 1.1B 1.07B 47.28B
Net Debt 4.48B 141M 123M 114M 106M 199M 13.26B 204M 1.37B 528M 6.55B 528M 516M 22.72B 4.04B 127M 111M 102M 95.93M 180M 11.96B 184M 1.23B 477M 5.91B 476M 466M 20.5B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
26/06/26 NT$37.20 -1.72% 2,086,139
25/06/26 NT$37.85 -1.05% 2,247,995
24/06/26 NT$38.25 +2.55% 3,462,556
23/06/26 NT$37.30 +0.95% 1,650,898
22/06/26 NT$36.95 -0.67% 2,548,830
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. 4123 Stock